Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 341.34M +409.5% |
| Revenue (ttm) | n/a |
| Net Income | -61.93M |
| EPS | -0.85 |
| Shares Out | 106.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 909,041 |
| Open | 3.270 |
| Previous Close | 3.240 |
| Day's Range | 3.185 - 3.350 |
| 52-Week Range | 1.803 - 8.000 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 10.75 (+235.94%) |
| Est. Earnings | Nov 12, 2026 |
About RLMD
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price target is $10.75, which is an increase of 235.94% from the latest price.
News
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics reports Q2 EPS (11c), consensus (20c)
As of June 30, 2026, the company’s cash, cash equivalents, and short-term investments balance was $217.7M, which is expected to provide sufficient resources to fund operations through 2029. “Relmada h...
Relmada Therapeutics Earnings Call Transcript: Q2 2026
Entered critical execution phase with strong cash position and leadership, advancing NDV-01 and sepranolone toward IND filings by year-end 2026. NDV-01 showed robust phase II efficacy and safety, with manufacturing scale-up and phase III trial readiness underway.
Relmada Therapeutics Quarterly report: Q2 2026
Relmada Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Relmada Therapeutics Earnings release: Q2 2026
Relmada Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Relmada Therapeutics appoints Bipin Dalmia as chief business officer
Relmada Therapeutics (RLMD) announced the appointment of Bipin Dalmia as chief business officer. Bipin will lead Relmada’s corporate strategy, commercial planning, and business development activities,...
Relmada Therapeutics names Bipin Dalmia chief business officer
Relmada Therapeutics (RLMD) announced the appointment of Bipin Dalmia as chief business officer. Dalmia will lead Relmada’s corporate strategy, commercial planning, and business development activities...
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics joins Russell 2000, Russell 3000 Indexes
Relmada Therapeutics (RLMD) announced that the company joined the Russell 2000 Index and the Russell 3000 Index effective after the U.S. market closed on June 26, as part of the…
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Relmada Therapeutics (RLMD) with a Buy rating and $12 price target The company’s NDV-01 is a “differentiated” sustained-release intravesical formulation for non-m...
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics Slides: Corporate presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
NDV-01, an extended-release gemcitabine/docetaxel, showed strong phase II results and is advancing to phase III in both high-risk and intermediate-risk bladder cancer. A pre-filled syringe formulation aims to expand use beyond academia, with robust IP and financial runway through 2029.
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics Transcript: AGM 2026
The meeting saw approval of all proposals, including director elections and amendments to the equity plan and articles. Strategic acquisitions and disciplined management led to a sharp rise in share price and market capitalization, positioning the company for future growth.
Relmada Therapeutics files automatic mixed securities shelf
16:54 EDT Relmada Therapeutics (RLMD) files automatic mixed securities shelf
Relmada Therapeutics Earnings Call Transcript: Q1 2026
Robust 12-month phase II data for NDV-01 in NMIBC, strong cash position after $160M financing, and phase III RESCUE program set to launch mid-2026. Patent filings may extend exclusivity to 2047, and cash runway is projected through 2029.
Relmada Therapeutics Quarterly report: Q1 2026
Relmada Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Relmada Therapeutics Earnings release: Q1 2026
Relmada Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and...
Relmada Therapeutics Slides: Company presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Relmada Therapeutics Slides: Corporate presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...